Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
By S. Walter, T. Weinschenk, A. Stenzl, R. Zdrojowy, A. Płużańska, C. Szczylik, M. Staehler, W. Brugger, P. Dietrich, R. Mendrzyk and 29 more. Nature Medicine, 2012
836 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/deac76546954724ab918927b6d08f5ae6a20a8bd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Therapeutic cancer vaccines. (2010, background): “A survival advantage was seen with some vaccines in phase II trials that was sometimes associated with an immune response to the vaccine in renal cell carcinoma (33), but no objective cancer regressions were noted.”
- Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells (2016, background): “Treg cell depletion has been reported to increase anti-tumor specific immune responses and to reduce tumor burden (Marabelle et al., 2013; Teng et al., 2010; Walter et al., 2012).”
- Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “This regimen led to immune responses that were associated with clinical responses (Walter et al., 2012).”
- Treatment of renal cell carcinoma: Current status and future directions (2017, background): “One of these strategies included IMA901, which is the first therapeutic vaccine consisting of multiple tumorassociated peptides (9 different class I human leucocyte antigens [HLA] [HLA-A*02] and 1 class II HLA), which were confirmed as naturally present in human cancer tissue.(103) IMA901 was studie”